Ptc Therapeutics (PTCT) Consolidated Net Income (2012 - 2026)

Ptc Therapeutics' Consolidated Net Income history runs 15 years deep, the most recent figure standing at $83.5 million for Q2 2026.

• In Q2 2026, Consolidated Net Income rose 228.75% year-over-year to $83.5 million; the TTM figure through Jun 2026 stood at $382.5 million (up 4.26% YoY), while the FY2025 annual figure was $1.1 billion, up 276.39% from the prior year.
• Consolidated Net Income for Q2 2026 stood at $83.5 million, up from -$2.8 million in the prior quarter.
• The five-year high for Consolidated Net Income was $866.6 million in Q1 2025, with the low at -$328.2 million in Q4 2024.
• The 5-year median for Consolidated Net Income is -$108.0 million (2022), against an average of -$40.0 million.
• The sharpest annual moves came in 2025 and 2026: Consolidated Net Income surged 1046.28% in 2025, then sank 100.32% in 2026.
• Ptc Therapeutics' Consolidated Net Income stood at -$174.5 million in 2022, then sank by 40.05% to -$244.4 million in 2023, then sank by 34.27% to -$328.2 million in 2024, then surged by 187.12% to $285.9 million in 2025, then plunged by 70.8% to $83.5 million in 2026.
• Business Quant data shows PTCT's Consolidated Net Income at $83.5 million in Q2 2026, -$2.8 million in Q1 2026, and $285.9 million in Q4 2025.